Comparative Pharmacokinetics of Vitamin K AntagonistsWarfarin, Phenprocoumon and Acenocoumarol

被引:0
|
作者
Mike Ufer
机构
[1] University Hospital Schleswig-Holstein,Institute of Pharmacology
[2] Karolinska University Hospital (Huddinge),Division of Clinical Pharmacology
[3] Karolinska Institute,Institute of Pharmacology
[4] University Hospital Schleswig-Holstein,undefined
来源
Clinical Pharmacokinetics | 2005年 / 44卷
关键词
Warfarin; Human Liver Microsome; Intrinsic Clearance; Phenprocoumon; Acenocoumarol;
D O I
暂无
中图分类号
学科分类号
摘要
Vitamin K antagonists belong to the group of most frequently used drugs worldwide. They are used for long-term anticoagulation therapy, and exhibit their anticoagulant effect by inhibition of vitamin K epoxide reductase. Each drug exists in two different enantiomeric forms and is administered orally as a race-mate. The use of vitamin K antagonists is complicated by a narrow therapeutic index and an unpredictable dose-response relationship, giving rise to frequent bleeding complications or insufficient anticoagulation. These large dose response variations are markedly influenced by pharmacokinetic aspects that are determined by genetic, environmental and possibly other yet unknown factors.
引用
收藏
页码:1227 / 1246
页数:19
相关论文
共 50 条
  • [31] DIFFERENTIAL EFFECT OF THE ENANTIOMERS OF PHENPROCOUMON AND WARFARIN ON THE VITAMIN-K1-EPOXIDE-VITAMIN-K1 RATIO IN RAT PLASMA
    SCHMIDT, W
    BEERMANN, D
    OESCH, F
    JAHNCHEN, E
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1979, 31 (07) : 490 - 491
  • [32] THE EFFECT OF FUROSEMIDE AND PROBENECID ON THE PHARMACOKINETICS OF PHENPROCOUMON
    MONIG, H
    BOHM, M
    OHNHAUS, EE
    ACTA PHARMACOLOGICA ET TOXICOLOGICA, 1986, 59 : 92 - 92
  • [33] BIOTRANSFORMATION AND PHARMACOKINETICS OF ACENOCOUMAROL (SINTROM) IN MAN
    DIETERLE, W
    FAIGLE, JW
    MONTIGEL, C
    SULC, M
    THEOBALD, W
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 11 (05) : 367 - 375
  • [34] Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon
    Verhoef, Talitha I.
    Redekop, William K.
    Daly, Ann K.
    van Schie, Rianne M. F.
    de Boer, Anthonius
    Maitland-van der Zee, Anke-Hilse
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (04) : 626 - 641
  • [35] COLLABORATIVE STUDY OF A SEMIAUTOMATED METHOD FOR ANALYSIS OF ACENOCOUMAROL, PHENPROCOUMON, AND POTASSIUM WARFARIN TABLETS
    KOLINSKI, RE
    JOURNAL OF THE ASSOCIATION OF OFFICIAL ANALYTICAL CHEMISTS, 1975, 58 (01): : 80 - 84
  • [36] Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs
    Penning-van Beest, FJA
    van Meegen, E
    Rosendaal, FR
    Stricker, BH
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (06) : 451 - 457
  • [37] The effect of nateglinide on the pharmacokinetics and pharmacodynamics, of acenocoumarol
    Sunkara, G
    Bigler, H
    Wang, Y
    Smith, H
    Prasad, P
    McLeod, J
    Ligueros-Saylan, M
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (01) : 41 - 48
  • [38] Comparative review of the pharmacokinetics of vitamin D analogues
    Bailie, GR
    Johnson, CA
    SEMINARS IN DIALYSIS, 2002, 15 (05) : 352 - 357
  • [39] INTOXICATION WITH PHENPROCOUMON (MARCOUMAR) PHARMACOKINETICS AND SIDE EFFECTS
    SEILER, K
    DUCKERT, F
    THROMBOSIS ET DIATHESIS HAEMORRHAGICA, 1969, 21 (02): : 320 - &
  • [40] Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: Effect on coagulation factor testing
    Walenga, Jeanine M.
    Drenth, Amanda F.
    Mayuga, Myttle
    Hoppensteadt, Debra A.
    Prechel, Margaret
    Harder, Sebastian
    Watanabe, Hikari
    Osakabe, Masanori
    Breddin, Hans-Klaus
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2008, 14 (03) : 325 - 331